What is the main reason for this 10-K amendment filing?

The primary reason for this amendment is to file an updated version of Exhibit 10(u), which is a Distribution Agreement between Merck & Co., Inc. and Centocor, Inc. dated April 3, 1998. Certain information from this exhibit has been redacted for confidential treatment.

Does this amendment change Merck's financial results for 2003?

No, this amendment specifically states that no other portions of the original 2003 Form 10-K are being amended. Therefore, it does not alter Merck's previously reported financial results for 2003.

What other exhibits are included in this filing?

In addition to the updated Exhibit 10(u), this filing also includes Exhibit 31.1, which relates to the Sarbanes-Oxley Act of 2002, Section 302 certifications.

Should investors rely on this filing for new strategic information about Merck?

This filing is an amendment focused solely on updating a specific exhibit. Investors should not expect to find new strategic information or comprehensive financial performance updates in this document. The original 2003 10-K would be the primary source for such information.

MRK 10-K FY2003 Annual Report — Revenue, Net Income, EPS

Summary

Merck & Co., Inc.'s 2003 Form 10-K, as amended on May 2, 2004, primarily serves to update Exhibit 10(u) concerning a Distribution Agreement with Centocor, Inc. dated April 3, 1998. This amendment does not alter the core financial statements or operational disclosures of the original filing, with the exception of certain omitted information from Exhibit 10(u) for which confidential treatment was requested. Investors should note that this filing is an amendment and not a restatement of the entire 2003 annual report.

Key Highlights

1Amendment to 2003 Form 10-K filing on May 2, 2004.
2The primary purpose of the amendment is to file an updated version of Exhibit 10(u), a Distribution Agreement with Centocor, Inc.
3Certain information within Exhibit 10(u) has been omitted due to a confidential treatment request to the SEC.
4No other portions of the original 2003 Form 10-K filing are amended by this filing.
5Exhibit 31.1, related to Sarbanes-Oxley Act of 2002, Section 302 certifications, is also included.
6This filing does not appear to provide new financial performance data or strategic updates beyond the specific exhibit amendment.

Merck & Co., Inc. Annual Report (Amendment), Year Ended Dec 31, 2003

Summary

Key Highlights

Frequently Asked Questions